Top

Published in:

01-08-2021 | Review

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Authors: Aysheh Alrfooh, Aditi Patel, Sandeep Laroia

Published in: Nuclear Medicine and Molecular Imaging | Issue 4/2021

Abstract

Liver tumors, both primary and secondary to metastatic disease, remain a major challenge, with an increasing incidence. In this context, taking advantage of the dual blood supply of the liver, and the fact that liver tumors derive majority of their blood supply from the hepatic artery, intraarterial therapies are gaining popularity. Intraarterial liver-directed therapy (IALDT) is the option when the surgery is not feasible due to the number of metastases or for other reasons. Transarterial radioembolization (TARE) is a specific type of IALDT, where a carrier particle/microsphere is labeled with a radioactive substance and then is injected into hepatic artery for therapeutic purposes. As this field is rapidly evolving, with multiple agents being investigated and being introduced into clinical practice, it is hard for the practitioners and researchers to encompass all the available information concisely. This article aims to present a comprehensive review of the prominent TARE technologies.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed

Ahmed I, Lobo DN. Malignant tumours of the liver. Surgery - Oxford International Edition. 2009;27:30–7.

Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol. 2016;65:1017–30.PubMedCrossRef

Page AJ, Weiss MJ, Pawlik TM. Surgical management of noncolorectal cancer liver metastases. Cancer. 2014;120:3111–21.PubMedCrossRef

Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver. 2016;10:332–9.PubMedPubMedCentralCrossRef

Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66:537–44.PubMedCrossRef

Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.PubMedCrossRef

Keane FK, Wo JY, Zhu AX, Hong TS. Liver-directed radiotherapy for hepatocellular carcinoma. Liver Cancer. 2016;5:198–209.PubMedPubMedCentralCrossRef

Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, et al. Therapeutic Strategies in HCC: Radiation modalities. Biomed Res Int. 2016;2016:1295329.PubMedPubMedCentralCrossRef

10.

Giunchedi P, Maestri M, Gavini E, Dionigi P, Rassu G. Transarterial chemoembolization of hepatocellular carcinoma—agents and drugs: an overview. Part 2. Expert Opin Drug Deliv. 2013;10:799–810.PubMedCrossRef

11.

Bozkurt MF, Salanci BV, Uğur Ö. Intra-arterial radionuclide therapies for liver tumors. Semin Nucl Med. 2016;46:324–39.PubMedCrossRef

12.

Bhagwat R, Vaidhya I. Novel drug delivery systems: an overview. Int J Pharm Sci Res; 2013. p. 970–82.

13.

Teow Y, Valiyaveettil S. Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. Nanoscale. 2010;2:2607–13.PubMedCrossRef

14.

Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Mol Clin Oncol. 2014;2:904–8.PubMedPubMedCentralCrossRef

15.

SM L. SIR-Spheres ® Y-90 resin microspheres (Yttrium-90 microspheres). Internet; 2017. p. 3–5.

16.

Schubiger PA, Beer HF, Geiger L, Rösler H, Zimmermann A, Triller J, et al. 90Y-resin particles—animal experiments on pigs with regard to the introduction of superselective embolization therapy. Int J Rad Appl Instrum B. 1991;18:305–11.PubMedCrossRef

17.

Subramanian S, Vimalnath KV, Dash A. Preparation and preliminary in vivo evaluation of. J Labelled Comp Radiopharm. 2018;61:509–14.PubMedCrossRef

18.

Turner JH, Claringbold PG, Klemp PF, Cameron PJ, Martindale AA, Glancy RJ, et al. 166Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig. Nucl Med Commun. 1994;15:545–53.PubMedCrossRef

19.

Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, et al. Transarterial Radioembolization (TARE) agents beyond. Biomed Res Int. 2018;2018:1435302.PubMedPubMedCentralCrossRef

20.

Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2005;32:980–9.PubMedCrossRef

21.

Piana PM, Bar V, Doyle L, Anne R, Sato T, Eschelman DJ, et al. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford). 2014;16:336–41.CrossRef

22.

Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–500.PubMedCrossRef

23.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Huijbregts JE, et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res. 2010;29:70.PubMedPubMedCentralCrossRef

24.

Jernigan SR, Osborne JA, Mirek CJ, Buckner G. Selective internal radiation therapy: quantifying distal penetration and distribution of resin and glass microspheres in a surrogate arterial model. J Vasc Interv Radiol. 2015;26:897-904.e2.PubMedCrossRef

25.

Gray. Polymer based radionuclide containing particulate material. 2002.

26.

Ehrhardt GJ, Day DE. Therapeutic use of 90Y microspheres. Int J Rad Appl Instrum B. 1987;14:233–42.PubMedCrossRef

27.

Burrill, Hafeli, Liu. Advances in radioembolization - embolics and isotopes. Nuclear Medicine Radiation Therapy. 2011:107.

28.

Basciano, Kleinstreuer, Kennedy AS. Computational fluid dynamics modeling of 90Y microspheres in human hepatic tumors. J Nuclear Med Radiat Ther. 2011.

29.

Conzone SD, Häfeli UO, Day DE, Ehrhardt GJ. Preparation and properties of radioactive rhenium glass microspheres intended for in vivo radioembolization therapy. J Biomed Mater Res. 1998;42:617–25.PubMedCrossRef

30.

Christie JK, Malik J, Tilocca A. Bioactive glasses as potential radioisotope vectors for in situ cancer therapy: investigating the structural effects of yttrium. Phys Chem Chem Phys. 2011;13:17749–55.PubMedCrossRef

31.

Ibrahim SM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, et al. Radiographic response to yttrium-90 radioembolization in anterior versus posterior liver segments. Cardiovasc Intervent Radiol. 2008;31:1124–32.PubMedCrossRef

32.

Brown RF, Lindesmith LC, Day DE. 166Holmium-containing glass for internal radiotherapy of tumors. Int J Rad Appl Instrum B. 1991;18:783–90.PubMedCrossRef

33.

Nijsen JF, van het Schip AD, Hennink WE, Rook DW, van Rijk PP, de Klerk JM. Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours. Curr Med Chem. 2002;9:73–82.PubMedCrossRef

34.

Mumper R, Jay M. Biodegradable radiotherapeutic polyestermicrospheres: optimization and in-vitro/in-vivo evaluation. J Control Release. 1992;18:193–203.CrossRef

35.

Doucet J, Kiri L, O'Connell K, Kehoe S, Lewandowski RJ, Liu DM, et al. Advances in degradable embolic microspheres: a state of the art review. J Funct Biomater. 2018;9.

36.

Yavari K, Yeganeh E, Abolghasemi H. Production and characterization of 166Ho polylactic acid microspheres. J Labelled Comp Radiopharm. 2016;59:24–9.PubMedCrossRef

37.

Chen G, Wei R, Huang X, Wang F, Chen Z. Synthesis and assessment of sodium alginate-modified silk fibroin microspheres as potential hepatic arterial embolization agent. Int J Biol Macromol. 2020;155:1450–9.PubMedCrossRef

38.

Ma Y, Li B, Li L, Duan LG, Wei YG, Chen XL. In vivo distribution of (131)I and (125)I dual-labeled gelatin microspheres after implantation into rabbit liver. Cancer Biother Radiopharm. 2012;27:267–75.PubMedCrossRef

39.

Häfeli UO, Roberts WK, Pauer GJ, Kraeft SK, Macklis RM. Stability of biodegradable radioactive rhenium (Re-186 and Re-188) microspheres after neutron-activation. Appl Radiat Isot. 2001;54:869–79.PubMedCrossRef

40.

Shukla J, Bandopadhyaya GP, Varma IK. 188Rhenium(V)-dimercaptosuccinic acid loaded poly(lactic-co-glycolic)acid microspheres for targeted radiotherapy: production and effectivity. Pharmazie. 2005;60:583–7.PubMed

41.

Nijsen JF, Zonnenberg BA, Woittiez JR, Rook DW, Swildens-van Woudenberg IA, van Rijk PP, et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med. 1999;26:699–704.PubMedCrossRef

42.

Mumper R, Jay M. Formation and stability of lanthanide complexes and their encapsulation into polymeric microspheres. The Journal of Physical Chemistry. 1992;96:8626–31.CrossRef

43.

Brandt M, Cardinale J, Giammei C, Guarrochena X, Happl B, Jouini N, et al. Mini-review: targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders. Nucl Med Biol. 2019;70:46–52.PubMedCrossRef

44.

Garin E, Boucher E, Rolland Y. 99mTc-MAA-based dosimetry for liver cancer treated using 90Y-loaded microspheres: known proof of effectiveness. J Nucl Med. 2014;55:1391–2.PubMedCrossRef

45.

Yang M, Hoppmann S, Chen L, Cheng Z. Human serum albumin conjugated biomolecules for cancer molecular imaging. Curr Pharm Des. 2012;18:1023–31.PubMedCrossRef

46.

Wunderlich G, Schiller E, Bergmann R, Pietzsch HJ. Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM). Nucl Med Biol. 2010;37:861–7.PubMedCrossRef

47.

Hunt AP, Frier M, Johnson RA, Berezenko S, Perkins AC. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur J Pharm Biopharm. 2006;62:26–31.PubMedCrossRef

48.

Chen LC, Lee WC, Ho CL, Chang YJ, Chen SJ, Chang CH. Biodistribution, Pharmacokinetics and Efficacy of. In Vivo. 2018;32:567–73.PubMedPubMedCentral

49.

Wunderlich G, Drews A, Kotzerke J. A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine. Appl Radiat Isot. 2005;62:915–8.PubMedCrossRef

50.

Wunderlich G, Pinkert J, Andreeff M, Stintz M, Knapp FF, Kropp J, et al. Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy. Appl Radiat Isot. 2000;52:63–8.PubMedCrossRef

51.

Pandey V, Tiwari N, A R, Das. Targeted drug delivery and gene therapy through natural biodegradable nanostructures in pharmaceuticals. Nanoarchitectonics in Biomedicine. 2019:437–72.

52.

Chi JL, Li CC, Xia CQ, Li L, Ma Y, Li JH, et al. Effect of (131)I gelatin microspheres on hepatocellular carcinoma in nude mice and its distribution after intratumoral injection. Radiat Res. 2014;181:416–24.PubMedCrossRef

53.

Ulubayram K, Eroglu I, Hasirci N. Gelatin microspheres and sponges for delivery of macromolecules. J Biomater Appl. 2002;16:227–41.PubMedCrossRef

54.

Ohta S, Nitta N, Takahashi M, Murata K, Tabata Y. Degradable gelatin microspheres as an embolic agent: an experimental study in a rabbit renal model. Korean J Radiol. 2007;8:418–28.PubMedPubMedCentralCrossRef

55.

Wang J, Tauchi Y, Deguchi Y, Morimoto K, Tabata Y, Ikada Y. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of H. pylori. Drug Deliv. 2000;7:237–43.PubMedCrossRef

56.

Ozeki M, Tabata Y. In vivo degradability of hydrogels prepared from different gelatins by various cross-linking methods. J Biomater Sci Polym Ed. 2005;16:549–61.PubMedCrossRef

57.

Lindegren S, Skarnemark G, Jacobsson L, Karlsson B. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate. Nucl Med Biol. 1998;25:659–65.PubMedCrossRef

58.

Nitta N, Ohta S, Tanaka T, Takazakura R, Nagatani Y, Kono N, et al. Gelatin microspheres: initial clinical experience for the transcatheter arterial embolization. Eur J Radiol. 2008;67:536–40.PubMedCrossRef

59.

Bing-Zheng L, Wang Li, Adhikari Mao. Preparation and characterization of crosslinked starch microspheres using a two-stage water-in-water emulsion method. Carbohydr Polym. 2012;88:912–6.CrossRef

60.

Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, et al. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:240–7.PubMedCrossRef

61.

Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, et al. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29:1285–92.PubMedCrossRef

62.

Selek H, Sahin S, Kas HS, Hincal AA, Ponchel G, Ercan MT, et al. Formulation and characterization of formaldehyde cross-linked degradable starch microspheres containing terbutaline sulfate. Drug Dev Ind Pharm. 2007;33:147–54.PubMedCrossRef

63.

Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, et al. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol. 2015;7:1694–700.PubMedPubMedCentralCrossRef

64.

Schicho A, Pereira PL, Pützler M, Michalik K, Albrecht T, Nolte-Ernsting C, et al. Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): results from a National Multi-Center Study on Safety and Efficacy. Med Sci Monit. 2017;23:796–800.PubMedPubMedCentralCrossRef

65.

Hajiramezanali M, Atyabi F, Mosayebnia M, Akhlaghi M, Geramifar P, Jalilian AR, et al. Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation. Int J Nanomedicine. 2019;14:2591–605.PubMedPubMedCentralCrossRef

66.

Hawary D, Motaleb M, Farag H, Guirguis O, Elsabee M. Water-soluble derivatives of chitosan as a target delivery system of 99mTc to some organs in vivo for nuclear imaging and biodistribution. J Radioanal Nucl Chem. 2011;290:557–67.CrossRef

67.

Wang J, Chen C. Chitosan-based biosorbents: modification and application for biosorption of heavy metals and radionuclides. Bioresour Technol. 2014;160:129–41.CrossRefPubMed

68.

Zielhuis SW, Seppenwoolde JH, Bakker CJ, Jahnz U, Zonnenberg BA, van het Schip AD, et al. Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications. J Biomed Mater Res A. 2007;82:892–8.PubMedCrossRef

69.

Uyen NTT, Hamid ZAA, Tram NXT, Ahmad N. Fabrication of alginate microspheres for drug delivery: a review. Int J Biol Macromol. 2020;153:1035–46.PubMedCrossRef

70.

Oerlemans C, Seevinck PR, van de Maat GH, Boulkhrif H, Bakker CJ, Hennink WE, et al. Alginate-lanthanide microspheres for MRI-guided embolotherapy. Acta Biomater. 2013;9:4681–7.PubMedCrossRef

71.

Jeong JM, Kim YJ, Lee YS, Ko JI, Son M, Lee DS, et al. Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. Nucl Med Biol. 2001;28:197–204.PubMedCrossRef

72.

Lee YS, Jeong JM, Kim YJ, Chung JW, Park JH, Suh YG, et al. Synthesis of 188 Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun. 2002;23:237–42.PubMedCrossRef

73.

Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology. 1985;154:15–7.PubMedCrossRef

74.

Lintia-Gaultier A, Perret C, Ansquer C, Eugène T, Kraeber-Bodéré F, Frampas E. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years’ experience. Nucl Med Commun. 2013;34:674–81.PubMedCrossRef

75.

Oger E, Lavenu A, Bellissant E, Garin E, Polard E. Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approach. Pharmacoepidemiol Drug Saf. 2011;20:956–63.PubMedCrossRef

76.

Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer. 2006;42:994–1003.PubMedCrossRef

Title: Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers
Authors: Aysheh Alrfooh
Aditi Patel
Sandeep Laroia
Publication date: 01-08-2021
Publisher: Springer Singapore
Published in: Nuclear Medicine and Molecular Imaging / Issue 4/2021
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-021-00709-3

At a glance: The STEP trials

Springer Medicine

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements

18F-FDG PET/CT Evaluation of Thymomas: a Pictorial Review

The Role of Tc-99 m-MIBI Scan in the Assessment of the Cystic Thyroid Nodule

KSNM60 in Cardiology: Regrowth After a Long Pause

Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68 Ga-PSMA PET/CT vs mpMRI

Does the Incremental Value of 123I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?